Compare Incyte Corporation (INCY) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vanguard S&P 500 ETF — how do they compare? Incyte Corporation trades at $120.7 (market cap $24.54B), while Vanguard S&P 500 ETF trades at $710.68. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | VOO | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $129.93 | $710.71 |
52-Week Low | $81.61 | $580.93 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
VOO trades at $710.69 with minimal daily movement (+0.01%), maintaining a bullish technical stance as the S&P 500 ETF approaches record highs. The overall technical signal is bullish with strong moving average support, though oscillators show neutral momentum. Recent news highlights the S&P 500's elevated valuation levels while institutional interest remains strong, with Bay Colony Advisory increasing its position by 8.6% in Q2 2026.
The ETF's outlook remains positive given its core exposure to large-cap US equities, but investors face valuation concerns with the S&P 500 trading at historically high multiples. Key risks include market volatility around inflation data and potential profit-taking near resistance levels, while institutional accumulation suggests continued confidence in the broader market trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
